Sumitomo Dainippon Pharma in JV for regenerative meds CDMO

9 October 2020

Sumitomo Dainippon Pharma and Sumitomo Chemical (TYO: 4005) have established S-RACMO Co, a joint venture company to develop manufacturing methods and manufacture products for the regenerative medicine and cell therapy field.

S-RACMO has started operations and will undertake business as a Contract Development and Manufacturing Organization (CDMO). The establishment of manufacturing systems is a major issue faced by academia and start-ups in the development and commercialization of regenerative medicine and cell therapy.

Sumitomo Chemical and Sumitomo Dainippon Pharma have decided to embark on the CDMO business to achieve the early diffusion and commercialization of regenerative medicine and cell therapy. They aim to leverage Sumitomo Chemical’s expertise in basic iPS/ES cell technologies and pharmaceutical contract manufacturing and Sumitomo Dainippon Pharma’s expertise gained by developing sophisticated manufacturing methods and pharmaceutical development through multiple projects in the regenerative medicine and cell therapy business.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK